Polycomb Repressive Complex 1 (PRC1) is a family of epigenetic regulators critical for mammalian development. Elucidating PRC1 composition and function across cell types and developmental stages is key to understanding the epigenetic regulation of cell fate determination. In this study, we discovered POGZ, a prominent Autism Spectrum Disorder (ASD) risk factor, as a novel component of PRC1.
View Article and Find Full Text PDFRibosomally synthesized and post-translationally modified peptides (RiPPs) are a growing class of natural products biosynthesized from a genetically encoded precursor peptide. RiPPs have attracted attention for the ability to generate and screen libraries of these compounds for useful biological activities. To facilitate this screening, it is useful to be able to do so with the leader peptide still present.
View Article and Find Full Text PDFAlthough men and women generally receive positive and negative reactions to childhood sexual abuse (CSA) disclosure (Filipas & Ullman, 2001), negative reactions are more common (Gagnier & Collin-Vézina, 2016). Negative disclosure reactions - such as disbelieving, retaliating against, or distracting the survivor - are both prevalent and associated with poorer post-abuse recovery and well-being (Kennedy & Prock, 2018; Ullman, 2010). For male survivors in particular, the responses one receives from others following disclosure may complicate one's sense of masculinity.
View Article and Find Full Text PDFTrends Endocrinol Metab
December 2024
Premenopausal women and endurance-trained individuals of either sex have reduced cardiovascular disease (CVD) risk. Endurance training shifts fuel selection towards fats to spare carbohydrates; interestingly, women prioritize fats as an energy resource more than men do during exercise. Relying on fats during exercise drives whole-body lipolysis and promotes lipid uptake and oxidation capacity in skeletal muscles.
View Article and Find Full Text PDFBMC Endocr Disord
December 2024
Background: Medications targeting the glucagon-like peptide-1 (GLP-1) pathway are an important therapeutic class currently used for the treatment of Type 2 diabetes (T2D). However, there is not enough known about which subgroups of patients would receive the most benefit from these medications.
Objective: The goal of this study was to develop a predictive model for patient responsiveness to medications, here collectively called GLP-1 M, that include GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP4) inhibitors (that normally degrade endogenously-produced GLP-1).